||WO||WO/2014/044230 - METHOD FOR OBTAINING 1-KESTOSE||27.03.2014||
||PCT/CU2013/000005||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||PÉREZ CRUZ, Enrique, Rosendo|
The invention relates to a method for obtaining 1-kestose on an industrial scale, using a recombinant fructosyltransferase (FTF) isolated from Festuca arundinacea, constitutively expressed in a non saccharolytic yeast host. According to the invention, the recombinant FTF of the sucrose:sucrose 1-fructosyltransferase (1-SSTrec) type is produced in a constitutive and stable manner and in high yields, both in the supernatant and in the cell sediment of the culture of a strain of Pichia pastoris. The invention also relates to a method for obtaining 1-SST on an industrial scale. The resulting recombinant enzyme is used for the mass enzymatic production of fructooligosaccharides (FOS), specifically 1-kestose, from sucrose. The method of the invention allows FOS conversion percentages greater than 55%, with 1-kestose being represented in more than 90%.
||WO||WO/2014/019555 - VESICLES WHICH INCLUDE EPIDERMAL GROWTH FACTOR AND COMPOSITIONS THAT CONTAIN SAME||06.02.2014||
||PCT/CU2013/000004||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||SANTANA MILIÁN, Héctor, Jesús|
The invention relates to vesicles which include epidermal growth factor (EGF), a cationic surface-active agent, and cholesterol or the derivatives thereof. The invention also discloses a method for preparing same using compressed fluid technology (FCs). The vesicles of the invention are useful in the production of drugs and cosmetic products, as well as in tissue engineering.
||WO||WO/2013/189467 - COMPOUNDS FROM THE FRUITS OF ACROCOMIA CRISPA AND ACROCOMIA ACULEATA AGAINST INFLAMMATION AND OXIDATIVE STRESS||27.12.2013||
||PCT/CU2013/000003||CENTRO NACIONAL DE INVESTIGACIONES CIENTIFICAS (CNIC)||GONZALES CANAVACIOLO, Victor Luis|
The invention relates to obtaining a novel active ingredient and to the method for obtaining same from the unripe or ripe fruits of Acrocomia crispa and/or Acrocomia aculeata, both from the Arecaceae family. The active ingredient can be used as a nutritional supplement, in cosmetic-therapeutic formulations or in pharmaceutical compositions for preventing and/or treating oxidative stress and inflammation. The ingredient includes a mixture of fatty acids (free and/or as acylglycerols or ethyl esters) having between 6 and 28 carbon atoms, mostly linear chain saturated having 8, 10, 12, 14, 16 and 18 carbon atoms and unsaturated having 16 and 18 carbon atoms. Said ingredient can also contain sterols and fatty alcohols having a high molecular weight.
||WO||WO/2013/143508 - METHOD FOR SIMULTANEOUS DETECTION, RECOVERY, IDENTIFICATION AND COUNTING OF MICROORGANISMS AND DEVICES FOR THE IMPLEMENTATION OF SAID METHOD||03.10.2013||
||PCT/CU2013/000002||CENTRO NACIONAL DE BIOPREPARADOS (BIOCEN)||RODRÍGUEZ MARTÍNEZ, Claudio|
The present invention describes a method and devices for the simultaneous detection, recovery, identification and counting of a plurality of microorganisms consisting in providing mixtures of nutrients specially selected from those that curtail the lag phase of growth in bacteria and moulds and which, together with fluorescent enzymatic, chromogenic or bioluminescent markers and other nutrient components or growth inhibitors, are embedded in three-dimensional structures or natural or artificial clays or ceramics with cavities of different dimensions and forms and specific surface areas of between 2 × 103 and 6 × 108 m2/m3.
||WO||WO/2013/127373 - RECOMBINANT ANTIBODIES HAVING DUAL SPECIFICITY FOR GANGLIOSIDES AND USE THEREOF||06.09.2013||
||PCT/CU2013/000001||CENTRO DE INMUNOLOGIA MOLECULAR||MORENO FRIAS, Ernesto|
The present invention relates to novel monoclonal antibodies and fragments of said antibodies, which have dual specificity and a high affinity for the gangliosides N-acetyl GM3 and N-glicolyl GM3, and which do not recognize other gangliosides. According to another aspect, the present invention relates to the use of said antibodies and the fragments thereof in tumor therapy, in which said tumors have a significant expression of any of the two antigens recognized by said antibodies, or a mixed expression of both antigens. The invention also relates to a use of said antibodies in the diagnosis of tumors that express at least one of the antigens.
||WO||WO/2013/113296 - COMPOSITION FROM LOBSTER HEMOCYTE EXTRACT FOR DETECTION OF LIPOPOLYSACCHARIDES, PEPTIDOGLYCANS AND 1,3-BETA-D-GLUCANS||08.08.2013||
||PCT/CU2012/000009||CENTRO DE INVESTIGACION Y DESARROLLO DE LOS MEDICAMENTOS(CIDEM)||PERDOMO MORALES, Rolando|
The present invention relates to the field of pharmaceuticals, chemistry and biotechnology and, in particular, to a method for preparing a composition for detecting and measuring the concentration of endotoxins or lipopolysaccharides, peptidoglycans and (1,3)-β-D-glucans, using a lobster hemocyte extract as starting material, to the modifications of the composition for increasing the sensitivity thereof, and to the methods for measuring endotoxins, peptidoglycans and (1,3)-β-D-glucans using said composition.
||WO||WO/2013/097835 - SPIROSTEROIDAL SYSTEMS HAVING NEUROACTIVE, ANTI-INFLAMMATORY EFFECTS||04.07.2013||
||PCT/CU2012/000008||CENTRO DE INVESTIGACION Y DESARROLLO DE LOS MEDICAMENTOS (CIDEM)||GARCIA PUPO, Laura|
The present invention relates to the fields of chemistry and pharmaceuticals and, in particular, to obtaining novel molecular entities — steroid derivatives — that affect the central nervous system. Diosgenin, which is a natural sapogenin, is used to obtain hexacyclic spirostanic steroid derivatives with the general formula I-IV, by reaction with compounds that can be oxidising, epoxidising, etc., as well as subsequent transformations of some of the latter. The molecular entities with the general formula I-IV contain the cyclopentanoperhydrophenanthrene core, in which the cycle A consists of spirostanic rings replaced with various electronegative atoms. Said molecular entities have anti-glutamatergic and anti-inflammatory action, and can be used for treating chronic and acute inflammatory, neurodegenerative, neuropsychiatric and neurological diseases.
||WO||WO/2013/097834 - PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TUMOURS THAT EXPRESS EGFR AND GANGLIOSIDE N-GLYCOLYL GM3 (NEUGCGM3)||04.07.2013||
||PCT/CU2012/000007||CENTRO DE INMUNOLOGIA MOLECULAR||GONZÁLEZ PALOMO, Adys|
The invention relates to pharmaceutical composition for the treatment of malignant tumours, in particular tumours that express EGFR and N-glycolyl GM3 ganglioside targets, in order to enhance the therapeutic effect produced individually by therapies against said targets. The pharmaceutical compositions of the invention comprise antibodies and/or vaccines against each of the targets. In addition, the invention relates to the methods used to apply the compositions of the invention.
||WO||WO/2013/064129 - ADJUVANTS FOR POLYSACCHARIDE VACCINES AND RESULTING FORMULATIONS||10.05.2013||
||PCT/CU2012/000006||INSTITUTO FINLAY. CENTRO DE INVESTIGACIÓN- PRODUCCIÓN DE SUEROS Y VACUNAS.||PEREZ MARTÍN, Oliver Germán|
The invention relates to immunogenic compositions for mucosal and parenteral application, comprising (1) a single capsular saccharide or multiple unconjugated bacteria and (2) potent adjuvants. Plain oligosaccharides or polysaccharides are preferred, without excluding the addition of potent adjuvants to conjugated polysaccharides. Preferably, the adjuvants are Adjuvant Finlay Cocleato x (AFCox) or Adjuvant Finlay Proteoliposome x (AFPLx). Mucosal delivery is preferred, without excluding parenteral delivery or combinations of both. The invention also relates to immunogenic compositions (a) a capsular saccharide antigen from serogroup C or serogroup A of Neisseria meningitidis; (b) AFPL1 adjuvants absorbed in alumina by parenteral route or non-absorbed AFPL1 or AFCol by nasal route; and (c) the application of both parenteral and mucosal priming simultaneously along with any of the potent adjuvants formulated with the aforementioned antigens. The use of potent adjuvants formulated with unconjugated polysaccharides increases the systemic mucosal immune response, polarising the independent Timo response of the polysaccharides to a dependent Timo response with a Th1 cellular pattern that guarantees the function thereof in small children and induces immune memory without requiring covalent conjugation.
||WO||WO/2013/044890 - AMINO ACID SEQUENCES FOR CONTROLLING PATHOGENS||04.04.2013||
||PCT/CU2012/000005||CENTRO DE INGENIERIA GENETICA Y BIOTECNOLOGIA||ACOSTA ALBA, Jannel|
The invention relates to isolated and purified antimicrobial peptides from tilapia (Oreochromis niloticus) gill extracts. Said peptides can be produced by chemical synthesis or in heterologous expression systems, such as bacteria and yeast, by conventional molecular biology techniques. Said peptides exhibit antimicrobial activity against various organisms including gram-positive bacteria, gram-negative bacteria, fungi and viruses. The invention also includes compositions for controlling pathogenic agents, comprising said antimicrobial peptides. The invention further relates to the use of said peptides as a molecular adjuvant in vaccine preparations.